Fig. 5: Spautin-1 induces DLBCL cell ferroptosis in combination with Dox or CTX. | Cell Death & Disease

Fig. 5: Spautin-1 induces DLBCL cell ferroptosis in combination with Dox or CTX.

From: USP13 dictates Ran turnover and vulnerability to ferroptosis in diffuse large B cell lymphoma (DLBCL)

Fig. 5

A Gene set enrichment analysis identified a gene set describing ferroptosis targets enriched upon treatment with Spautin-1 in TMD8 cells. B Quantitative Real-time PCR indicating expression of NQO1 and ALOX12 treated with Spautin-1 (10 μM) for 36 h in TMD8 (left) and SU-DHL-2 (right) cells. C The morphology of mitochondria in TMD8 (upper) or SU-DHL-2 (lower) cells treated as control, with Spautin-1 (40 μM) or with erastin for 48 h visualized by transmission electron microscopy. The scale was 1 μm. D The Lipid peroxide level was examined after treatment with Dox (1 μM), Spautin-1(10 μM) or in combination or erastin (2 μM) by using Lipid Peroxidation MDA Assay Kit in WSU-DLCL-2 (left) or U2932 (right) cells. E The Lipid peroxide level was examined after treatment with CTX (20 μM), Spautin-1(10 μM) or in combination or erastin (2 μM) by using Lipid Peroxidation MDA Assay Kit in WSU-DLCL-2 (left) or U2932 (right) cells. F The mitochondrial membrane potential was quantified by inverted fluorescence microscope using TMRE probe in SU-DHL-2 (upper) or TMD8 (lower) cells after treatment with Dox (1 μM), Spautin-1(10 μM) or in combination or erastin (2 μM) for 48 h. The fluorescence intensity was visualized as bar chart (left: SU-DHL-2; right: TMD8). G The mitochondrial membrane potential was quantified by inverted fluorescence microscope using TMRE probe in SU-DHL-2 (upper) or TMD8 (lower) cells after treatment with CTX (20 μM), Spautin-1(10 μM) or in combination or erastin (2 μM) for 48 h. The fluorescence intensity was visualized as bar chart (left: SU-DHL-2; right: TMD8). H The ROS level was quantified by inverted fluorescence microscope in DLBCL cells after treatment with Dox (1 μM), Spautin-1(10 μM), or in combination or erastin (2 μM) using DCFH-DA probe in U2932 (upper) or WSU-DLCL-2 (lower) cells. The fluorescence intensity was visualized as bar chart (left: U2932; right: WSU-DLCL-2). I The ROS level was quantified by inverted fluorescence microscope in DLBCL cells after treatment with CTX (20 μM), Spautin-1(10 μM) or in combination or erastin (2 μM) using DCFH-DA probe in U2932 (upper) or WSU-DLCL-2 (lower) cells. The fluorescence intensity was visualized as bar chart (left: U2932; right: WSU-DLCL-2).

Back to article page